Given the central role of chronic inflammation in NAFLD progression, the ability of Rh2 to modulate immune cell responses indirectly through hepatocyte signaling provides valuable insight into its therapeutic potential. Here, RHAG is linked to metabolic dysfunction-associated steatotic liver disease.